Symbols / NEO Stock $9.02 +4.76% NeoGenomics, Inc.

Healthcare • Diagnostics & Research • United States • NCM
NEO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. Anthony P. Zook
Exch · Country NCM · United States
Market Cap 1.17B
Enterprise Value 1.42B
Income -108.03M
Sales 727.33M
FCF (ttm) 17.20M
Book/sh 6.49
Cash/sh 1.23
Employees 2,500
Insider 10d —
IPO Mar 16, 2004
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 27.93
PEG —
P/S 1.61
P/B 1.39
P/C —
EV/EBITDA -780.20
EV/Sales 1.95
Quick Ratio 3.61
Current Ratio 4.26
Debt/Eq 48.95
LT Debt/Eq —
EPS (ttm) -0.84
EPS next Y 0.32
EPS Growth —
Revenue Growth 10.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-28
Earnings (prior) 2026-04-28
ROA -2.90%
ROE -12.43%
ROIC —
Gross Margin 43.16%
Oper. Margin -6.56%
Profit Margin -14.85%
Shs Outstand 130.14M
Shs Float 118.99M
Insider Own 1.65%
Instit Own 102.61%
Short Float 7.13%
Short Ratio 4.97
Short Interest 7.88M
52W High 13.74
vs 52W High -34.35%
52W Low 4.72
vs 52W Low 91.10%
Beta 1.71
Impl. Vol. 35.42%
Rel Volume 1.50
Avg Volume 1.92M
Volume 2.89M
Target (mean) $14.06
Tgt Median $13.50
Tgt Low $12.00
Tgt High $17.00
# Analysts 8
Recom Buy
Prev Close $8.61
Price $9.02
Change 4.76%
About

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.06
Mean price target
2. Current target
$9.02
Latest analyst target
3. DCF / Fair value
$2.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.02
Low
$12.00
High
$17.00
Mean
$14.06

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-24 main Piper Sandler Overweight → Overweight $13
2026-02-17 main Needham Buy → Buy $15
2026-01-12 reit Needham Buy → Buy $14
2025-09-12 main TD Cowen Buy → Buy $12
2025-09-02 main Stephens & Co. Overweight → Overweight $11
2025-08-29 main Needham Buy → Buy $14
2025-08-04 main Piper Sandler Overweight → Overweight $11
2025-07-30 main Morgan Stanley Equal-Weight → Equal-Weight $8
2025-07-29 down William Blair Outperform → Market Perform —
2025-07-29 main Needham Buy → Buy $8
2025-05-06 main Piper Sandler Overweight → Overweight $12
2025-05-01 main Morgan Stanley Equal-Weight → Equal-Weight $10
2025-04-30 main Goldman Sachs Buy → Buy $10
2025-04-30 down Leerink Partners Outperform → Market Perform $9
2025-04-29 main Needham Buy → Buy $9
2025-04-17 main Goldman Sachs Buy → Buy $15
2025-02-26 main Piper Sandler Overweight → Overweight $18
2025-02-19 main B of A Securities Neutral → Neutral $16
2025-02-19 main Needham Buy → Buy $18
2025-01-28 main Goldman Sachs Buy → Buy $18
News
RSS: Latest NEO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 STONE WARREN President — 17,562 — —
2026-04-01 ZOOK ANTHONY P Chief Executive Officer — 140,498 — —
2026-02-23 SHERMAN JEFFREY SCOTT Chief Financial Officer — 57,693 — —
2026-02-23 OLIVO ALICIA C General Counsel — 29,522 — —
2026-02-23 STONE WARREN President — 36,548 — —
2026-02-20 AUNAN GREGORY D Officer — 6,323 — —
2026-01-20 STONE WARREN President — 22,128 $12.50 $276,682
2026-01-13 OLIVO ALICIA C General Counsel — 59,382 — —
2026-01-13 STONE WARREN President — 59,382 — —
2025-11-25 OLIVO ALICIA C General Counsel — 20,916 $12.00 $250,992
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
727.33
+10.11%
660.57
+11.65%
591.64
+16.07%
509.73
Operating Revenue
727.33
+10.11%
660.57
+11.65%
591.64
+16.07%
509.73
Cost Of Revenue
413.04
+11.49%
370.47
+6.75%
347.04
+7.83%
321.83
Reconciled Cost Of Revenue
378.91
+14.19%
331.81
+7.58%
308.44
+8.16%
285.17
Gross Profit
314.29
+8.34%
290.10
+18.60%
244.60
+30.18%
187.90
Operating Expense
402.42
+7.16%
375.55
+10.05%
341.25
+0.07%
341.00
Research And Development
37.08
+18.99%
31.16
+14.10%
27.31
-9.95%
30.33
Selling General And Administration
331.65
+6.81%
310.49
+10.91%
279.96
+0.74%
277.91
Selling And Marketing Expense
91.92
+8.62%
84.62
+19.46%
70.84
+5.23%
67.32
General And Administrative Expense
239.74
+6.14%
225.87
+8.01%
209.12
-0.70%
210.59
Other Gand A
239.74
+6.14%
225.87
+8.01%
209.12
-0.70%
210.59
Total Expenses
815.46
+9.31%
746.01
+8.39%
688.29
+3.84%
662.84
Operating Income
-88.13
-3.14%
-85.45
+11.59%
-96.65
+36.88%
-153.11
Total Operating Income As Reported
-115.88
-25.81%
-92.11
+14.51%
-107.74
+31.65%
-157.62
EBITDA
-38.69
-2460.62%
-1.51
+91.42%
-17.61
+78.61%
-82.33
Normalized EBITDA
-10.94
-312.51%
5.15
+178.95%
-6.52
+91.62%
-77.81
Reconciled Depreciation
67.82
-6.51%
72.55
-0.05%
72.58
+4.54%
69.43
EBIT
-106.52
-43.83%
-74.06
+17.89%
-90.19
+40.57%
-151.76
Total Unusual Items
-27.75
-316.84%
-6.66
+39.95%
-11.09
-145.53%
-4.52
Total Unusual Items Excluding Goodwill
-27.75
-316.84%
-6.66
+39.95%
-11.09
-145.53%
-4.52
Special Income Charges
-27.75
-316.84%
-6.66
+39.95%
-11.09
-145.53%
-4.52
Impairment Of Capital Assets
27.75
0.00
0.00
—
Restructuring And Mergern Acquisition
0.00
-100.00%
6.66
-39.95%
11.09
+145.53%
4.52
Net Income
-108.03
-37.22%
-78.73
+10.51%
-87.97
+39.02%
-144.25
Pretax Income
-110.27
-36.68%
-80.67
+16.91%
-97.10
+39.06%
-159.34
Net Non Operating Interest Income Expense
5.32
-54.98%
11.81
+18.16%
9.99
+763.68%
-1.51
Interest Expense Non Operating
3.75
-43.28%
6.62
-4.20%
6.91
-8.89%
7.58
Net Interest Income
5.32
-54.98%
11.81
+18.16%
9.99
+763.68%
-1.51
Interest Expense
3.75
-43.28%
6.62
-4.20%
6.91
-8.89%
7.58
Interest Income Non Operating
9.07
-50.78%
18.43
+9.02%
16.90
+178.22%
6.08
Interest Income
9.07
-50.78%
18.43
+9.02%
16.90
+178.22%
6.08
Other Income Expense
-27.46
-290.18%
-7.04
+32.62%
-10.44
-120.85%
-4.73
Other Non Operating Income Expenses
0.30
+178.10%
-0.38
-158.85%
0.64
+402.35%
-0.21
Tax Provision
-2.24
-15.08%
-1.95
+78.65%
-9.13
+39.51%
-15.09
Tax Rate For Calcs
0.00
-16.12%
0.00
-74.26%
0.00
-0.63%
0.00
Tax Effect Of Unusual Items
-0.56
-249.66%
-0.16
+84.54%
-1.04
-143.97%
-0.43
Net Income Including Noncontrolling Interests
-108.03
-37.22%
-78.73
+10.51%
-87.97
+39.02%
-144.25
Net Income From Continuing Operation Net Minority Interest
-108.03
-37.22%
-78.73
+10.51%
-87.97
+39.02%
-144.25
Net Income From Continuing And Discontinued Operation
-108.03
-37.22%
-78.73
+10.51%
-87.97
+39.02%
-144.25
Net Income Continuous Operations
-108.03
-37.22%
-78.73
+10.51%
-87.97
+39.02%
-144.25
Normalized Income
-80.84
-11.92%
-72.23
+7.31%
-77.92
+44.41%
-140.16
Net Income Common Stockholders
-108.03
-37.22%
-78.73
+10.51%
-87.97
+39.02%
-144.25
Diluted EPS
-0.84
-35.48%
-0.62
+11.43%
-0.70
+39.66%
-1.16
Basic EPS
-0.84
-35.48%
-0.62
+11.43%
-0.70
+39.66%
-1.16
Basic Average Shares
128.10
+1.14%
126.66
+0.92%
125.50
+1.03%
124.22
Diluted Average Shares
128.10
+1.14%
126.66
+0.92%
125.50
+1.03%
124.22
Diluted NI Availto Com Stockholders
-108.03
-37.22%
-78.73
+10.51%
-87.97
+39.02%
-144.25
Amortization
12.80
-7.27%
13.81
-10.89%
15.49
+5.80%
14.65
Amortization Of Intangibles Income Statement
12.80
-7.27%
13.81
-10.89%
15.49
+5.80%
14.65
Depreciation Amortization Depletion Income Statement
33.69
-0.60%
33.90
-0.26%
33.98
+3.70%
32.77
Depreciation And Amortization In Income Statement
33.69
-0.60%
33.90
-0.26%
33.98
+3.70%
32.77
Depreciation Income Statement
20.89
+3.99%
20.09
+8.65%
18.49
+2.01%
18.12
Earnings From Equity Interest
—
—
0.00
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,359.83
-16.98%
1,638.04
-2.57%
1,681.23
-3.38%
1,740.03
Current Assets
376.29
-36.87%
596.02
-0.13%
596.81
-1.40%
605.29
Cash Cash Equivalents And Short Term Investments
159.62
-58.74%
386.84
-6.83%
415.20
-5.20%
437.99
Cash And Cash Equivalents
159.62
-56.51%
367.01
+7.16%
342.49
+30.13%
263.18
Other Short Term Investments
0.00
-100.00%
19.83
-72.73%
72.72
-58.40%
174.81
Receivables
159.24
+5.78%
150.54
+14.72%
131.23
+9.62%
119.71
Accounts Receivable
159.24
+5.78%
150.54
+14.72%
131.23
+9.62%
119.71
Inventory
28.57
+6.80%
26.75
+10.73%
24.16
-0.50%
24.28
Prepaid Assets
21.44
+6.34%
20.16
+12.11%
17.99
+18.05%
15.24
Assets Held For Sale Current
—
—
—
0.00
Other Current Assets
7.42
-36.73%
11.72
+42.27%
8.24
+2.01%
8.08
Total Non Current Assets
983.54
-5.61%
1,042.02
-3.91%
1,084.42
-4.44%
1,134.74
Net PPE
163.28
-5.99%
173.69
-5.49%
183.78
-7.47%
198.61
Gross PPE
372.33
+2.38%
363.68
+6.34%
341.99
+3.47%
330.54
Accumulated Depreciation
-209.06
-10.04%
-189.99
-20.09%
-158.21
-19.92%
-131.93
Properties
0.00
0.00
0.00
0.00
Land And Improvements
—
—
—
—
Buildings And Improvements
—
—
—
—
Machinery Furniture Equipment
122.51
+5.00%
116.67
+18.06%
98.82
+10.70%
89.27
Construction In Progress
7.73
-9.21%
8.51
+135.63%
3.61
-59.80%
8.98
Other Properties
182.69
+0.98%
180.92
-4.94%
190.33
+1.31%
187.87
Leases
59.41
+3.19%
57.57
+16.95%
49.23
+10.83%
44.42
Goodwill And Other Intangible Assets
810.87
-5.98%
862.45
-3.73%
895.89
-3.77%
931.03
Goodwill
524.34
+0.30%
522.77
+0.00%
522.77
+0.00%
522.77
Other Intangible Assets
286.53
-15.65%
339.68
-8.96%
373.13
-8.61%
408.26
Investments And Advances
—
—
—
—
Long Term Equity Investment
—
—
—
—
Other Non Current Assets
9.39
+59.60%
5.89
+24.12%
4.74
-7.18%
5.11
Total Liabilities Net Minority Interest
523.27
-28.87%
735.70
-0.54%
739.69
-0.31%
742.01
Current Liabilities
88.30
-70.69%
301.24
+212.80%
96.30
+7.09%
89.93
Payables And Accrued Expenses
35.09
+2.52%
34.23
-3.31%
35.40
-0.50%
35.58
Payables
23.09
+6.86%
21.61
+6.26%
20.33
-0.86%
20.51
Accounts Payable
23.09
+6.86%
21.61
+6.26%
20.33
-0.86%
20.51
Current Accrued Expenses
12.00
-4.92%
12.62
-16.23%
15.07
-0.01%
15.07
Pensionand Other Post Retirement Benefit Plans Current
47.58
-23.80%
62.44
+17.46%
53.16
+32.44%
40.14
Current Debt And Capital Lease Obligation
4.78
-97.66%
204.16
+3539.18%
5.61
-15.69%
6.65
Current Debt
—
200.78
—
—
Other Current Borrowings
—
200.78
—
—
Current Capital Lease Obligation
4.78
+41.26%
3.38
-39.73%
5.61
-15.69%
6.65
Current Deferred Liabilities
0.85
+108.07%
0.41
-80.80%
2.13
-71.81%
7.56
Current Deferred Revenue
0.85
+108.07%
0.41
-80.80%
2.13
-71.81%
7.56
Total Non Current Liabilities Net Minority Interest
434.97
+0.12%
434.46
-32.47%
643.39
-1.33%
652.08
Long Term Debt And Capital Lease Obligation
404.68
+0.87%
401.18
-33.81%
606.07
+0.30%
604.27
Long Term Debt
341.86
+0.45%
340.33
-36.76%
538.20
+0.54%
535.32
Long Term Capital Lease Obligation
62.82
+3.26%
60.84
-10.36%
67.87
-1.57%
68.95
Non Current Deferred Liabilities
18.22
-15.30%
21.51
-11.43%
24.29
-30.12%
34.75
Non Current Deferred Taxes Liabilities
18.22
-15.30%
21.51
-11.43%
24.29
-30.12%
34.75
Other Non Current Liabilities
12.07
+2.52%
11.77
-9.68%
13.03
-0.16%
13.05
Stockholders Equity
836.56
-7.29%
902.34
-4.16%
941.54
-5.66%
998.02
Common Stock Equity
836.56
-7.29%
902.34
-4.16%
941.54
-5.66%
998.02
Capital Stock
0.13
+0.78%
0.13
+0.79%
0.13
+0.00%
0.13
Common Stock
0.13
+0.78%
0.13
+0.79%
0.13
+0.00%
0.13
Share Issued
128.99
+0.66%
128.15
+0.61%
127.37
+0.36%
126.91
Ordinary Shares Number
128.99
+0.66%
128.15
+0.61%
127.37
+0.36%
126.91
Additional Paid In Capital
1,270.23
+3.42%
1,228.20
+3.20%
1,190.14
+2.52%
1,160.88
Retained Earnings
-433.81
-33.16%
-325.78
-31.87%
-247.06
-55.30%
-159.09
Gains Losses Not Affecting Retained Earnings
0.00
+101.94%
-0.21
+87.69%
-1.67
+57.07%
-3.90
Other Equity Adjustments
0.00
+101.94%
-0.21
+87.69%
-1.67
+57.07%
-3.90
Total Equity Gross Minority Interest
836.56
-7.29%
902.34
-4.16%
941.54
-5.66%
998.02
Total Capitalization
1,178.42
-5.17%
1,242.67
-16.02%
1,479.73
-3.50%
1,533.35
Working Capital
287.99
-2.30%
294.78
-41.10%
500.51
-2.88%
515.36
Invested Capital
1,178.42
-18.36%
1,443.45
-2.45%
1,479.73
-3.50%
1,533.35
Total Debt
409.46
-32.36%
605.33
-1.04%
611.68
+0.12%
610.93
Net Debt
182.24
+4.68%
174.10
-11.04%
195.71
-28.09%
272.14
Capital Lease Obligations
67.60
+5.26%
64.22
-12.60%
73.48
-2.81%
75.61
Net Tangible Assets
25.69
-35.60%
39.89
-12.60%
45.64
-31.87%
67.00
Tangible Book Value
25.69
-35.60%
39.89
-12.60%
45.64
-31.87%
67.00
Investmentsin Associatesat Cost
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
5.23
-25.53%
7.02
+459.60%
-1.95
+97.04%
-65.99
Cash Flow From Continuing Operating Activities
5.23
-25.53%
7.02
+459.60%
-1.95
+97.04%
-65.99
Net Income From Continuing Operations
-108.03
-37.22%
-78.73
+10.51%
-87.97
+39.02%
-144.25
Depreciation Amortization Depletion
67.82
-6.51%
72.55
-0.05%
72.58
+4.54%
69.43
Depreciation
36.07
-7.75%
39.10
+4.41%
37.45
+5.87%
35.37
Amortization Cash Flow
31.75
-5.06%
33.45
-4.80%
35.13
+3.16%
34.06
Depreciation And Amortization
67.82
-6.51%
72.55
-0.05%
72.58
+4.54%
69.43
Amortization Of Intangibles
31.75
-5.06%
33.45
-4.80%
35.13
+3.16%
34.06
Other Non Cash Items
8.43
-29.89%
12.02
-2.27%
12.30
-14.18%
14.33
Stock Based Compensation
41.32
+23.65%
33.41
+35.64%
24.63
-0.16%
24.67
Asset Impairment Charge
27.75
+6067.33%
0.45
-73.58%
1.70
+137.19%
0.72
Operating Gains Losses
0.03
+163.27%
-0.05
-116.78%
0.29
-63.95%
0.81
Change In Working Capital
-32.09
+1.64%
-32.63
-28.00%
-25.49
+19.58%
-31.70
Change In Receivables
-6.18
+68.01%
-19.31
-67.71%
-11.52
-51.91%
-7.58
Changes In Account Receivables
-6.18
+68.01%
-19.31
-67.71%
-11.52
-51.91%
-7.58
Change In Inventory
-1.54
+42.83%
-2.70
-494.49%
-0.45
+58.73%
-1.10
Change In Prepaid Assets
1.55
+122.76%
-6.83
-114.81%
-3.18
-174.14%
-1.16
Change In Payables And Accrued Expense
-20.36
-485.37%
5.28
-37.66%
8.47
+203.15%
2.79
Change In Accrued Expense
-15.66
-268.75%
9.28
-28.70%
13.02
+608.76%
1.84
Change In Payable
-4.69
-17.22%
-4.00
+12.01%
-4.55
-574.63%
0.96
Change In Account Payable
-4.69
-17.22%
-4.00
+12.01%
-4.55
-574.63%
0.96
Change In Other Working Capital
-3.36
-9.41%
-3.07
+72.57%
-11.19
+30.47%
-16.10
Change In Other Current Assets
—
—
—
-8.56
Change In Other Current Liabilities
-2.21
+63.08%
-6.00
+21.30%
-7.62
+10.92%
-8.56
Investing Cash Flow
-12.34
-195.96%
12.86
-83.24%
76.71
+14736.94%
0.52
Cash Flow From Continuing Investing Activities
-12.34
-195.96%
12.86
-83.24%
76.71
+14736.94%
0.52
Net PPE Purchase And Sale
-27.01
+34.22%
-41.06
-42.81%
-28.75
+6.92%
-30.89
Purchase Of PPE
-27.01
+34.22%
-41.06
-42.81%
-28.75
+6.92%
-30.89
Capital Expenditure
-27.01
+34.22%
-41.06
-42.81%
-28.75
+6.92%
-30.89
Net Investment Purchase And Sale
19.56
-63.72%
53.92
-48.87%
105.46
+446.14%
19.31
Purchase Of Investment
-0.50
0.00
+100.00%
-6.76
+93.08%
-97.61
Sale Of Investment
20.06
-62.79%
53.92
-51.95%
112.22
-4.02%
116.92
Net Business Purchase And Sale
-6.45
0.00
0.00
0.00
Purchase Of Business
-6.45
0.00
0.00
0.00
Net Other Investing Changes
1.57
—
—
12.10
Financing Cash Flow
-200.29
-4410.98%
4.65
+2.02%
4.55
-61.50%
11.83
Cash Flow From Continuing Financing Activities
-200.29
-4410.98%
4.65
+2.02%
4.55
-61.50%
11.83
Net Issuance Payments Of Debt
-201.25
0.00
0.00
0.00
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
-201.25
0.00
0.00
0.00
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
-201.25
0.00
0.00
0.00
Net Long Term Debt Issuance
-201.25
0.00
0.00
0.00
Net Common Stock Issuance
0.96
-79.29%
4.65
+0.48%
4.62
-63.26%
12.59
Net Other Financing Charges
—
—
-0.07
+90.77%
-0.76
Changes In Cash
-207.39
-945.68%
24.52
-69.08%
79.31
+247.83%
-53.65
Beginning Cash Position
367.01
+7.16%
342.49
+30.13%
263.18
-16.93%
316.83
End Cash Position
159.62
-56.51%
367.01
+7.16%
342.49
+30.13%
263.18
Free Cash Flow
-21.78
+36.02%
-34.04
-10.85%
-30.70
+68.31%
-96.88
Interest Paid Supplemental Data
1.69
-55.84%
3.83
+13.28%
3.38
-0.71%
3.40
Income Tax Paid Supplemental Data
0.52
+148.79%
0.21
+18.29%
0.17
-2.78%
0.18
Common Stock Issuance
0.96
-79.29%
4.65
+0.48%
4.62
-63.26%
12.59
Earnings Losses From Equity Investments
—
—
0.00
0.00
Issuance Of Capital Stock
0.96
-79.29%
4.65
+0.48%
4.62
-63.26%
12.59
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category